Download PDF
Horm Metab Res 1985; 17(6): 306-307
DOI: 10.1055/s-2007-1013525
Clinical

© Georg Thieme Verlag, Stuttgart · New York

Deranged Metabolism of Cyclic Nucleotides in Liver Diseases

T. Matsushima, H. Maekubo, T. Yoshida, H. Taneda, J. Yoshida, T. Miyazaki, F. Okada1
  • Third Department of Internal Medicine, Hokkaido University School of Medicine, Sapporo, Japan
  • 1Health Administration Center, Hokkaido University, Hokkaido, Japan
Further Information

Publication History

1983

1984

Publication Date:
14 March 2008 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

To clarify the factor(s) responsible for changes in the plasma cyclic GMP concentration in liver diseases, we measured the plasma levels of cyclic GMP, along with cyclic AMP, in various clinical stages of chronic liver diseases and acute hepatitis. The level of cyclic GMP was found to increase significantly in the early stage of acute hepatitis, in the decompensated stage of liver cirrhosis, and in malignant diseases. In the former two states, it is postulated that decreased hepatic mass is responsible for the changes in the plasma cyclic GMP concentration. The retension rate of indocyanin green (ICGR15) was highly correlated with the plasma cyclic GMP level. The result suggests that the determination of plasma cyclic GMP is useful as an index of the reserve function of the liver in disease states.

Key-Words:

Cyclic GMP - Liver Disease - Reserve Function - ICGR15